Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.71 |
| ▸ | CNR2 | P34972 | 9/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367349 | 1.00 | CNR1 (0.71) | CNR1CNR2HTTKMT2AALDH1A1 | |
| SCHEMBL5623690 | 1.00 | CNR1 (0.71) | CNR1CNR2HTTKMT2AALDH1A1 | |
| SCHEMBL5623970 | 1.00 | CNR1 (0.71) | CNR1CNR2HTTKMT2AALDH1A1 | |
| SCHEMBL14367348 | 1.00 | CNR1 (0.71) | CNR1CNR2HTTKMT2AALDH1A1 | |
| SCHEMBL14367335 | 0.84 | CNR2 (0.81) | CNR1CNR2ALDH1A1L3MBTL1 | |
| SCHEMBL14367340 | 0.84 | CNR2 (0.81) | CNR1CNR2ALDH1A1L3MBTL1 | |
| SCHEMBL5623108 | 0.84 | CNR2 (0.81) | CNR1CNR2ALDH1A1L3MBTL1 | |
| SCHEMBL5623688 | 0.84 | CNR2 (0.83) | CNR1CNR2 | |
| SCHEMBL14367347 | 0.84 | CNR2 (0.83) | CNR1CNR2 | |
| SCHEMBL14367345 | 0.83 | CNR2 (1.00) | CNR1CNR2KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | CNR2, TRPV1, CNR1 | CNR1 3/4885CNR2 1/4885HTT 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.